What Happened?
Philadelphia, PA-based XyloCor Appointed Alexander Gaidamaka as Senior Vice President of Technology, Manufacturing and Quality
About the Company
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.
About the Person
Alexander Gaidamaka is Senior Vice President of Technology, Manufacturing and Quality at XyloCor. Previously, Alexander held various senior IT leadership roles in the industry.
Info Source
News
Short Profile